Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of diagnostic and therapeutic products. The company focuses on the field of "molecularly-targeted radiation" (MTR), aiming to provide improved solutions for serious conditions such as cancer. Their portfolio includes a range of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer.

The company was established in 2017 and has since grown by bringing together a set of complementary technologies and expertise. Telix Pharmaceuticals has a global footprint with operations in Japan, Belgium and the United States, in addition to its headquarters in Australia. The company's mission is to help patients live longer, better lives by creating products that can diagnose and treat serious diseases with higher precision.

Connect